Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial

BACKGROUND: Achievement of durable responses in patients with relapsed/refractory peripheral T cell lymphoma (PTCL) is challenging with current therapies, and there are few data regarding the potential benefits of continuing treatment in patients with the best response of stable disease (SD). Histon...

Descripción completa

Detalles Bibliográficos
Autores principales: Foss, Francine, Horwitz, Steven, Pro, Barbara, Prince, H. Miles, Sokol, Lubomir, Balser, Barbara, Wolfson, Julie, Coiffier, Bertrand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4785666/
https://www.ncbi.nlm.nih.gov/pubmed/26965915
http://dx.doi.org/10.1186/s13045-016-0243-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4785666/
https://www.ncbi.nlm.nih.gov/pubmed/26965915
http://dx.doi.org/10.1186/s13045-016-0243-8

Ejemplares similares